| Study characteristics |
| Methods |
Prospective, randomised, open‐label, blinded, endpoint trial in 46 stroke units in Germany |
| Participants |
Individuals aged > 18 years presenting with symptoms of an acute ischaemic stroke causing measurable neurological defect (NIHSS 5 to 20). Randomised and treated within 24 hours |
| Interventions |
Aspirin 25 mg and extended‐release dipyridamole 200 mg twice daily vs 100 mg aspirin once daily |
| Outcomes |
mRS score and vascular adverse events (non‐fatal stroke, TIA, non‐fatal MI, and bleeding complications) |
| Notes |
Subset |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
Randomised using a pseudorandom number generator |
| Allocation concealment (selection bias) |
Low risk |
Through telephone interview |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
Open‐label |
| Blinding of outcome assessment (detection bias)
All outcomes |
Low risk |
Blinded |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
20% discontinued treatment due to various causes |
| Selective reporting (reporting bias) |
Low risk |
All expected outcomes reported |
